Clinical Trials Browser

Tertiary Lymphoid Structures, Biliary Tract Neoplasms, Carcinoma, Non-Small-Cell Lung, Sarcoma, Colorectal Neoplasms, Triple Negative Breast Neoplasms

NCT04756765 2025-08-17

Talazoparib Monotherapy in PALB2 Mutation Associated Advanced Breast Cancer

Phase 2 Withdrawn

Breast

Breast Neoplasms

NCT06762808 2025-08-15

Phase II Study of Atezolizumab and Tiragolumab With ctDNA for HPV-positive SCC

Phase 2 Withdrawn

Tumor-Agnostic

Carcinoma, Squamous Cell

NCT04118036 2025-08-11

Abemaciclib + Pembrolizumab In Glioblastoma

Phase 2 Withdrawn

CNS

Glioblastoma

NCT06498518 2025-07-11

PRIMUS006

Phase 2 Withdrawn

Gastrointestinal

Pancreatic Neoplasms

NCT06508827 2025-07-09

Intravenous Iron in Combination With Standard of Care Immunotherapy in Melanoma

Phase 2 Withdrawn

Classical hematologyDermatologic

Anemia, Melanoma, Anemia, Iron-Deficiency

NCT05620914 2025-06-15

PARAMETer

Phase 2 Withdrawn

CNS

Brain Neoplasms

NCT05840770 2025-05-26

Cemiplimab for the Treatment of Untreated Brain Metastases From PD-L1 >= 50% Non-Small Cell Lung Cancer

Phase 2 Withdrawn

CNSThoracic

Brain Neoplasms, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT06361758 2025-05-23

Second-line Treatment With CAdonilimab and LEnvatinib for Unresectable HCC

Phase 2 Withdrawn

Gastrointestinal

Carcinoma, Hepatocellular

NCT04685915 2025-05-22

Copanlisib Plus Ibrutinib or Acalabrutinib in R/R CLL

Phase 2 Withdrawn

LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell

NCT06895577 2025-05-21

Neoadjuvant Chemoradiotherapy Plus Sintilimab for MSS, Locally Advanced Rectal Cancer-

Phase 2 Withdrawn

Gastrointestinal

Rectal Neoplasms

NCT01125449 2025-05-18

Study of High Dose Intravenous (IV) Ascorbic Acid in Measurable Solid Tumor Disease

Phase 2 Withdrawn

Plasma cellSarcoma

Adenocarcinoma, Carcinoma, Multiple Myeloma, Sarcoma, Desmoplastic Small Round Cell Tumor

NCT03879811 2025-05-15

Determining the Effects of Temozolomide Followed by Nivolumab in Patients With Colorectal Cancer

Phase 2 Withdrawn

Gastrointestinal

Colorectal Neoplasms

NCT04329221 2025-05-07

Immunotherapy Before Transplantation for Skin Cancer Prevention in Organ Transplant Recipients

Phase 2 Withdrawn

Dermatologic

Carcinoma, Squamous Cell, Skin Neoplasms, Keratosis, Actinic

NCT04642287 2025-05-07

Immunotherapy After Transplantation for Skin Cancer Prevention in Organ Transplant Recipients

Phase 2 Withdrawn

Dermatologic

Carcinoma, Squamous Cell, Skin Neoplasms, Keratosis, Actinic

NCT03288818 2025-04-29

Low Dose Total Skin Electron Beam Radiation Therapy and Mechlorethamine Hydrochloride Gel in Treating Patients With Mycosis Fungoides

Phase 2 Withdrawn

Lymphoid

Mycosis Fungoides

NCT03374852 2025-04-29

CPI-613 in Combination With Modified FOLFIRINOX in Patients With Locally Advanced Pancreatic Cancer

Phase 2 Withdrawn

Gastrointestinal

Pancreatic Ductal Adenocarcinoma

NCT02939807 2025-04-27

A Phase II Study of ABC294640 as Monotherapy in Patients With Advanced Hepatocellular Carcinoma

Phase 2 Withdrawn

Gastrointestinal

Carcinoma, Hepatocellular, Liver Neoplasms

NCT04595981 2025-04-27

Chemo-embolization for Head and Neck Cancer

Phase 2 Withdrawn

Head & Neck

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Squamous Cell

NCT06522360 2025-04-24

Brigatinib Plus Chemotherapy or Local Consolidation Therapy in ALK Positive Advanced Non-small Cell Lung Cancer (BrightStar-2)

Phase 2 Withdrawn

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT03581500 2025-04-23

Hyperpolarized Carbon C 13 Pyruvate Magnetic Resonance Spectroscopic Imaging in Predicting Treatment Response in Patients With Prostate Cancer

Phase 2 Withdrawn

Genitourinary

Prostatic Neoplasms

NCT05766514 2025-04-22

Trial of Cladribine and Low-Dose Cytarabine (LoDAC) Alternating With Decitabine vs. Hypomethylating Agents (HMA) Plus Venetoclax as Frontline Therapy for AML or High-Grade MDS in Patients Unfit for Intensive Induction

Phase 2 Withdrawn

MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

NCT05815316 2025-04-13

18F-PSMA PET/MRI for the Diagnosis of Clinically Significant Prostate Cancer

Phase 2 Withdrawn

Genitourinary

Prostatic Neoplasms

NCT05608369 2025-04-04

HPV

Phase 2 Withdrawn

Head & Neck

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Squamous Cell

NCT04180761 2025-04-03

ProPeC

Phase 2 Withdrawn

Gastrointestinal

Stomach Neoplasms

NCT06351306 2025-03-24

DEC-C and Thioguanine for R/R AML

Phase 2 Withdrawn

Other hematologic neoplasm

Neoplasms, Leukemia, Myeloid, Acute

NCT03541486 2025-03-10

XACT-PANC-2

Phase 2 Withdrawn

Gastrointestinal

Pancreatic Neoplasms

NCT06352866 2025-03-03

Siltuximab for Cytokine Release Syndrome Prophylaxis Prior to tx w/ Teclistamab in RRMM

Phase 2 Withdrawn

Plasma cell

Cytokine Release Syndrome, Multiple Myeloma

NCT06494787 2025-02-24

SOC-2320

Phase 2 Withdrawn

Sarcoma